Fitusiran · Qfitlia
RNA / oligonucleotide
Evidence outlook
Approved: Hemophilia A and B
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Partial signal
Also approved (1)
- Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and pediatric patients 12 years of age and older with severe hemophilia A or B (Qfitlia; NMPA)
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT03417245 NCT03417245 · Hemophilia A and B This trial was randomized with a real active comparator (on-demand factor treatment) and used a hard clinical endpoint -- annualized bleeding rate -- which showed a large, statistically significant reduction with fitusiran. However, the study was open-label (no blinding of patients or investigators), which is a meaningful limitation for a trial where treatment decisions for 'breakthrough bleeds' involve some clinical judgment, so this falls short of the strongest evidence tier despite the otherwise solid randomized, controlled design and clear positive result. Registry: NCT03417245 | 3 | Estimated Annualized Bleeding Rate (ABR) for Treated Bleeds During the Efficacy Period (From Day 29 up to Day 246 or up to the last day of bleeding follow up (any day up to Day 246), whichever was the earliest); Observed Annualized Bleeding Rate (ABR) for Treated Bleeds During the Efficacy Period (From Day 29 up to Day 246 or up to the last day of bleeding follow up (any day up to Day 246), whichever was the earliest) 2021-01-26 | Estimated mean annualised bleeding rate: 3·1 fitusiran vs 31·0 on-demand factor (rate ratio 0·101; p<0·0001) | Partial signal | link ↗ |
View 5 more trials
ATLAS-PPX NCT03549871 · Hemophilia A and B There was no randomization, no blinding, and no concurrent control group -- patients were compared only to their own pre-study bleeding rates, which is a weaker design than a parallel-group trial regardless of how the numbers came out. Even though the bleeding-rate endpoint is a hard, clinically meaningful measure and the overall combined analysis reached significance, published cohort-level results were mixed (one comparison significant, the other not), and the single-arm, open-label design caps this as weak evidence. Registry: NCT03549871 | 3 | Estimated Annualized Bleeding Rate (ABR) (Factor/BPA prophylaxis period: Day -168 to Day -1 or up to last day of bleeding follow up (any day up to Day -1); 6-month fitusiran efficacy period: Day 29 to Day 190 or up to last day of bleeding follow up (any day up to Day 190), whichever was earliest); Observed Annualized Bleeding Rate (ABR) (Factor/BPA prophylaxis period: Day -168 to Day -1 or up to last day of bleeding follow up (any day up to Day -1); 6-month fitusiran efficacy period: Day 29 to Day 190 or up to last day of bleeding follow up (any day up to Day 190), whichever was earliest) 2022-01-20 | Estimated mean ABR reduced by 79.7% (P = .0021) and 46.4% (P = .0598) vs BPA/CFC prophylaxis, respectively | Weak signal | link ↗ |
ATLAS-NEO NCT05662319 · Hemophilia A and B Registry: NCT05662319 | 3 | Annualized bleeding rate (ABR) in the fitusiran primary efficacy period (Day 169 to Day 505 (since the first dose of fitusiran)) 2027-03-25 | In progress: results expected 25 Mar 2027 | not yet graded | link ↗ |
ATLAS-KIDS NCT07285460 · Hemophilia A and B Registry: NCT07285460 | 3 | Annualized treated bleeding rate (ABR) in the fitusiran primary efficacy period and in the SOC period (Day 85 to Day 421 (fitusiran primary efficacy period); Day -168 to Day -1 (SOC period)) 2029-08-04 | In progress: results expected 4 Aug 2029 | not yet graded | link ↗ |
ATLAS-INH NCT03417102 · Hemophilia A and B The study randomized 57 participants to fitusiran or on-demand bypassing agents, but treatment assignment was not blinded, and the primary comparison was based on a clinical bleeding-rate endpoint. The estimated primary endpoint favored fitusiran significantly, while the observed bleeding-rate endpoint was descriptive; the open-label design and small study population support a moderate evidence grade rather than a strong one. Registry: NCT03417102 | 3 | Estimated Annualized Bleeding Rate (ABR) for Treated Bleeds During the Efficacy Period (From Day 29 up to Day 246 or up to the last day of bleeding follow up (any day up to Day 246), whichever was the earliest); Observed Annualized Bleeding Rate (ABR) for Treated Bleeds During the Efficacy Period (From Day 29 up to Day 246 or up to the last day of bleeding follow up (any day up to Day 246), whichever was the earliest) 2020-11-25 | Completed. Key figures are not recorded here; the rationale explains the result. | Partial signal | link ↗ |
ATLAS-OLE NCT03754790 · Hemophilia Registry: NCT03754790 | 3 | Number of participants with treatment emergent adverse events (TEAEs) (from study baseline (day 1) up to maximum 88 months) 2026-09-14 | Results not posted; external-source review pending | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (6)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (1)
What this study did
Phase 1/2 (1)
What this study did
Phase 4 (1)
What this study did
Competitive landscape
This drug's own stage for Hemophilia A and B: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Fitusiran (Qfitlia): this drug | Approved | RNA / oligonucleotide | Antithrombin (SERPINC1) mRNA | Partial signal | NCT03417245: Estimated mean annualised bleeding rate: 3·1 fitusiran vs 31·0 on-demand factor (rate ratio 0·101; p<0·0001) NCT03549871: Estimated mean ABR reduced by 79.7% (P = .0021) and 46.4% (P = .0598) vs BPA/CFC prophylaxis, respectively | |
| Zemocimig | Phase 1(overall) | Multispecific antibody | — | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(3 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Qfitlia (Fitusiran) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.